Agenda
� 3:00-3:30 PM Networking & Registration
� 3:30-5:00 PM Experts Panel
� 5:00-6:30 PM Wine & Cheese Networking Reception
A decade ago, the most successful bioscience business model was the fully-integrated company, from R&D; to manufacturing to sales. Today, companies operate all along the drug/device discovery value chain and no company can exist without a robust alliance and partnership strategy. This panel will explore the fundamentals and case studies of successful � and unsuccessful - partnerships. This session discusses the elements of a partnership/alliance strategy and how to identify partners and targets, from a variety of perspectives: The Big Company, The Acquired Company, The Investor, The Lawyer and all moderated by your very own dynamic and interactive professor, Ron Star of Howard Rice. Panelists will look at the view from each side examining:
� When and why to partner
� Elements of a partnership/alliance strategy
� What to outsource/in license based on product portfolio & life cycle
� Identifying alliance partners and acquisition targets
� IP management
� Disclosure processes
� Deal structures
� Required internal structures, processes, decision making
�Big Company� Perspective
Martin Babler
VP of Immunology Sales and Marketing, Genentech
Martin Babler is VP of Immunology Sales and Marketing at Genentech with responsibility for Xolair, Rituxan Immunology and the late stage Immunology pipeline. Prior to his current role Martin was Senior Director and head of Commercial Development in charge of marketing and strategic input for all products in Genentech's pipeline across the different therapeutic areas. His team was focused on creating high value assets in close collaboration with Research and Development and introduced several new tools and systems to the organization that help optimize product launches. Martin joined Genentech several years ago as Director of Marketing in the Cardiovascular Franchise. Prior to joining Genentech, Martin held various roles of increasing responsibility in sales, sales management, marketing and business development on a global as well as affiliate level with Eli Lilly and Company.
Martin Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.
"Investor Perspective"
Craig Taylor
Partner, Alloy Ventures
Craig C. Taylor has been an active venture capitalist since 1977. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford in 1977. He worked in the Office of Technology Licensing at Stanford from 1975 to 1977. He is a director of Adeza Biomedical (NASDAQ:ADZA), Pharmacyclics (NASDAQ:PCYC) and Solexa (NASDAQ:SLXA), all public companies. He serves on the boards of several private companies, including ForteBio, Galileo Pharmaceuticals, K2 Optronics, Labcyte, Optimedica, and Zyomyx. Mr. Taylor is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory.
�Acquisition Perspective�
David Summa
President & CEO, Acumen Pharmaceuticals
David Summa is currently the President and CEO of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease.
Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline. Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto. Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice. Dave received his BS and MS from MIT in the department of Chemical Engineering.
�Biz Dev Perspective�
Charlotte Rogers
Business Development and Marketing
Charlotte Rogers is a seasoned executive with more than 15 years of business development, and marketing experience in pre-IPO, mid-sized and large multi-national corporations specializing in therapeutics, diagnostics and genomic technologies. She provides business development and marketing consulting services to clients ranging from pre-Series A to publicly traded companies. Charlotte has an outstanding record of creative deal-making to generate cash, accelerate product development, maximize product commercialization, and leverage relationships to increase post-deal success. She has numerous closed in- and out-licensing licensing transactions valued at over $240 million. Charlotte has spearheaded portfolio prioritization, life-cycle planning, and directed commercial strategy for products with projected revenues exceeding $2 billion. She is an expert at forecasting emerging markets, and accurately projected the value of the erectile dysfunction market several years prior to the launch of Viagra�. Most recently, she was Vice President, Business Development at NuGEN, a genomics company. She successfully built the company with the founders by transitioning the company from an incubator, completing two rounds of financing, and bringing two genomic products to market in three years. Charlotte has held management positions at Syntex, Roche, Neurex, Elan and IntraBiotics. She holds an M.B.A, and B.S. from Santa Clara University.
Moderator & �Legal Perspective�
Ron Star
Director, Howard Rice
Faculty Member, Entrepreneurship, UC Berkeley
Mr. Star is a director of the firm focusing on securities law, financings, venture capital, intellectual property and mergers and acquisitions. He works closely with start-up and private companies on issues related to equity and financings, intellectual property matters, the structuring of executive compensation (including stock arrangements), strategic ventures, acquisitions and management buy-outs. He was recognized as a Northern California Super Lawyer in 2004 and 2005 by Law & Politics, which published a list of the winners in San Francisco magazine. Mr. Star's engagements run the gamut from representing start-up companies in formation to representing major multinational companies in strategic investments. His particular industry specialties include computer software and hardware, semiconductors, information services businesses, internet and multimedia companies, medical technology, food related companies, retail operations and financial services companies.
Mr. Star is a lecturer at the Haas School of Business at the University of California at Berkeley, and teaches a second year MBA course on entrepreneurship. He is a guest lecturer at Stanford University's Graduate School of Business. He also has been a member of the faculty of the San Francisco State Multimedia Studies Program, and is a frequent lecturer on venture capital transactions, acquisitions, computer law, multimedia, strategic partnerships, employment matters and closely held businesses.
His representative clients include Transmeta Corporation, Tower Semiconductor, Ltd., Maxager Technology, Inc., Artemis Medical Inc., Allegis Capital, Sofinnova Ventures, Rheodyne, L.P., Reiter Affiliated Companies, Vocera Communications, Navis Corporation and Steeleye Technology, Inc. Mr. Star has a J.D., Harvard Law School (magna cum laude) editor, Harvard Law Review, editor-at-large, Harvard Environmental Law Review, a M.B.A., Harvard Business School (with distinction), and a B.A., Harvard University (magna cum laude).
